Literature DB >> 1312695

Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants.

J H Tong1, S Dong, J P Geng, W Huang, Z Y Wang, G L Sun, S J Chen, Z Chen, C J Larsen, R Berger.   

Abstract

Genomic DNA probes generated from the retinoic acid receptor alpha (RARA) gene located on chromosome 17 and from the MYL gene located on chromosome 15 were used to study the chromosome 15 breakpoints resulting from the t(15; 17) translocation in 26 patients with acute promyelocytic leukemia (APL). In 20 out of 22 patients with a detectable MYL rearrangement, the breakpoints were clustered within a 4.4 kb segment designated MYLbcr. The two remaining patients exhibited a more 5' rearrangement at about 10 kb upstream of the MYLbcr region, implying the lack of at least one MYL gene exon in the resulting MYL-RARA fusion gene. The variation of chromosome breakpoints within the MYL gene may explain size heterogeneity previously observed in some MYL-RARA fusion transcripts expressed in APL cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312695

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.

Authors:  S Dong; J Zhu; A Reid; P Strutt; F Guidez; H J Zhong; Z Y Wang; J Licht; S Waxman; C Chomienne; Z Chen; A Zelent; S J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

2.  Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.

Authors:  Bai-Wei Gu; Hui Xiong; Yan Zhou; Bing Chen; Li Wang; Shuo Dong; Zhi-Yuan Yu; Ling-Feng Lu; Ming Zhong; Hai-Feng Yin; Gen-Feng Zhu; Wei Huang; Shuang-Xi Ren; Robert E Gallagher; Samuel Waxman; Guo-Qiang Chen; Zhu-Gang Wang; Zhu Chen; Gang Fu; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 3.  Analysis of phenotype-genotype connection: the story of dissecting disease pathogenesis in genomic era in China, and beyond.

Authors:  Yan Shen; Qi Xu; Zeguang Han; Han Liu; Guang-Biao Zhou
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

4.  Quantitative detection of PML-RARalpha fusion transcript by real-time PCR with a single primer pair.

Authors:  Mariko Takenokuchi; Yuji Nakamachi; Keiko Yoneda; Kana Joo; Seiji Kawano; Eiji Tatsumi; Katsuyasu Saigo; Shunichi Kumagai
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

5.  Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A.

Authors:  Yoshihito Uchino; Noriyoshi Iriyama; Yoshihiro Hatta; Masami Takei
Journal:  Cancer Cell Int       Date:  2015-03-12       Impact factor: 5.722

6.  PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR.

Authors:  A Perez; P Kastner; S Sethi; Y Lutz; C Reibel; P Chambon
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

7.  Molecular heterogeneity of the PML gene rearrangement in acute promyelocytic leukemia: prevalence and clinical significance.

Authors:  H Fukutani; T Naoe; H Yoshida; S Yamamori; R Ohno
Journal:  Jpn J Cancer Res       Date:  1993-03

Review 8.  Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy.

Authors:  Viera Dobrotkova; Petr Chlapek; Pavel Mazanek; Jaroslav Sterba; Renata Veselska
Journal:  BMC Cancer       Date:  2018-11-01       Impact factor: 4.430

Review 9.  Human genome research in China.

Authors:  Boqin Qiang
Journal:  J Mol Med (Berl)       Date:  2004-04       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.